Description
Polivy Injection Uses
Polivy (Polatuzumab Vedotin-piiq) is a CD79b-directed antibody drug conjugate used in combination with medications bendamustine and a rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, following at least two prior therapies.
Dosage: The recommended dose of Polivy is 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles along with bendamustine and a rituximab. Subsequent infusions may be administered over 30 minutes in case the previous infusion is tolerated. Premedicate with an antihistamine and antipyretic before polatuzumab vedotin. If a planned polivy dose is missed, administer as soon as possible. Adjust the schedule of administration to maintain a 21-day interval between doses.
Side Effects: The most commonly reported polatuzumab vedotin side effects include:
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Fatigue
- Diarrhea
- Pyrexia
- Decreased appetite
- Pneumonia
Warnings and Precautions:
- Monitor patients with polatuzumab vedotin for infusion-related reactions during the infusion and for a minimum of 90 minutes after the initial dose.
- Administer an antipyretic and antihistamine prior to the use of polivy, and monitor patients closely throughout the infusion.
- Monitor patients with polivy uses for signs of peripheral neuropathy such as hyperesthesia, hypoesthesia, gait disturbance, paresthesia, dysesthesia, neuropathic pain, burning sensation, or weakness.
- Patients with polatuzumab vedotin 140 mg injection should be monitored for complete blood counts throughout treatment.
- Females of reproductive potential are advised of the potential risk to a fetus and should contact their healthcare professional if they become pregnant, or if pregnancy is suspected, during therapy with polatuzumab vedotin.
- Women with polatuzumab vedotin fda label medication are advised to avoid breastfeeding while on polatuzumab vedotin and for at least two months following the last dose.
Reviews
There are no reviews yet.